GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JBM (Healthcare) Ltd (HKSE:02161) » Definitions » ROE %

JBM (Healthcare) (HKSE:02161) ROE % : 13.78% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is JBM (Healthcare) ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. JBM (Healthcare)'s annualized net income for the quarter that ended in Mar. 2024 was HK$136.0 Mil. JBM (Healthcare)'s average Total Stockholders Equity over the quarter that ended in Mar. 2024 was HK$986.7 Mil. Therefore, JBM (Healthcare)'s annualized ROE % for the quarter that ended in Mar. 2024 was 13.78%.

The historical rank and industry rank for JBM (Healthcare)'s ROE % or its related term are showing as below:

HKSE:02161' s ROE % Range Over the Past 10 Years
Min: 2.68   Med: 10.19   Max: 43.61
Current: 16.62

During the past 7 years, JBM (Healthcare)'s highest ROE % was 43.61%. The lowest was 2.68%. And the median was 10.19%.

HKSE:02161's ROE % is ranked better than
83.33% of 966 companies
in the Drug Manufacturers industry
Industry Median: 4.485 vs HKSE:02161: 16.62

JBM (Healthcare) ROE % Historical Data

The historical data trend for JBM (Healthcare)'s ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JBM (Healthcare) ROE % Chart

JBM (Healthcare) Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROE %
Get a 7-Day Free Trial 10.19 2.89 2.68 5.96 13.34

JBM (Healthcare) Semi-Annual Data
Mar18 Mar19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.61 7.38 12.57 13.78 19.76

Competitive Comparison of JBM (Healthcare)'s ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JBM (Healthcare)'s ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s ROE % distribution charts can be found below:

* The bar in red indicates where JBM (Healthcare)'s ROE % falls into.



JBM (Healthcare) ROE % Calculation

JBM (Healthcare)'s annualized ROE % for the fiscal year that ended in Mar. 2024 is calculated as

ROE %=Net Income (A: Mar. 2024 )/( (Total Stockholders Equity (A: Mar. 2023 )+Total Stockholders Equity (A: Mar. 2024 ))/ count )
=130.463/( (985.509+970.676)/ 2 )
=130.463/978.0925
=13.34 %

JBM (Healthcare)'s annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=136.004/( (1002.773+970.676)/ 2 )
=136.004/986.7245
=13.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


JBM (Healthcare)  (HKSE:02161) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=136.004/986.7245
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(136.004 / 643.174)*(643.174 / 1410.9485)*(1410.9485 / 986.7245)
=Net Margin %*Asset Turnover*Equity Multiplier
=21.15 %*0.4558*1.4299
=ROA %*Equity Multiplier
=9.64 %*1.4299
=13.78 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=136.004/986.7245
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (136.004 / 168.312) * (168.312 / 157.962) * (157.962 / 643.174) * (643.174 / 1410.9485) * (1410.9485 / 986.7245)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.808 * 1.0655 * 24.56 % * 0.4558 * 1.4299
=13.78 %

Note: The net income data used here is two times the semi-annual (Mar. 2024) net income data. The Revenue data used here is two times the semi-annual (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


JBM (Healthcare) ROE % Related Terms

Thank you for viewing the detailed overview of JBM (Healthcare)'s ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


JBM (Healthcare) Business Description

Traded in Other Exchanges
N/A
Address
108 Wai Yip Street, Units 808-811, 8 floor, C-Bons International Centre, Kwun Tong, Kowloon, Hong Kong, HKG
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
Executives
Ubs Trustees (b.v.i.) Limited
Kingshill Development Group Inc
Sum Kwong Yip, Derek
Queenshill Development Limited
Lincoln's Hill Development Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si
New Heritage Healthcare Limited 2101 Beneficial owner
Gavett Limited 2201 Interest of corporation controlled by you
United Islands Group Limited 2201 Interest of corporation controlled by you
Fortstar Limited 2201 Interest of corporation controlled by you
Tao Richard 2201 Interest of corporation controlled by you
Hon Hing Tong Patricia 2202 Interest of your spouse
Tao Paul 2201 Interest of corporation controlled by you
Choi Siu Ping 2202 Interest of your spouse
Longjin Investments Limited 2101 Beneficial owner

JBM (Healthcare) Headlines

No Headlines